nilotinib (Nanocopoeia)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Namenilotinib (Nanocopoeia)
Drug Alias Namenilotinib
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDiscoidin domain receptors inhibitorsPlatelet-derived growth factor receptor inhibitorsStem cell growth factor receptor inhibitors +[4] 
TargetsStem cell growth factor receptorBcr-Abl tyrosine kinaseDiscoidin domain receptors +[4] 
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanocopoeia LLC
China Registration ClassN/A

Develop Information

Active CompaniesNanocopoeia LLC
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A